Who are HA 0.3%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Synvisc-One, viscosupplementation 1+1+1, High hyal Plus inj., Synovian inj.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ha-0-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

HA 0.3% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HA 0.3% (HA 0.3%) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hyaluronic acid derivative. Area: Ophthalmology or Dermatology.

phase 3 Hyaluronic acid derivative Hyaluronic acid receptors (CD44, RHAMM) Ophthalmology or Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

HA 0.3% (HA 0.3%) — Huons Co., Ltd.. HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HA 0.3% TARGET	HA 0.3%	Huons Co., Ltd.	phase 3	Hyaluronic acid derivative	Hyaluronic acid receptors (CD44, RHAMM)
Synvisc-One	Synvisc-One	Nature Cell Co. Ltd.	marketed	Viscosupplement; hyaluronic acid derivative	Synovial fluid; joint cartilage surfaces
viscosupplementation 1+1+1	viscosupplementation 1+1+1	University of Sao Paulo General Hospital	marketed	Hyaluronic acid derivative; viscosupplement	Hyaluronic acid receptor (CD44); joint synovial fluid
High hyal Plus inj.	High hyal Plus inj.	Huons Co., Ltd.	phase 3	Hyaluronic acid derivative	Hyaluronic acid receptors (CD44, RHAMM)
Synovian inj	Synovian inj	Shin Poong Pharmaceutical Co. Ltd.	phase 3	Hyaluronic acid derivative; viscosupplement	Hyaluronic acid receptor (CD44); joint synovial fluid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hyaluronic acid derivative class)

Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HA 0.3% — Competitive Intelligence Brief. https://druglandscape.com/ci/ha-0-3. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab